Plus, news about Replimmune, Novo Nordisk and Biosplice:
Avidity Biosciences is looking for $300M in stock sale: The RNA company is planning a $300 million public offering on the heels of an early-stage readout of a treatment for a form of muscular dystrophy called facioscapulohumeral muscular dystrophy. — Lei Lei Wu
Rapport Therapeutics raises $174M from IPO, private placement: Last week, the neuroscience company listed on the Nasdaq and announced a concurrent stock sale to private investors. Rapport is developing a suite of former Johnson & Johnson compounds for neurological disorders. — Lei Lei Wu
Replimune’s $100M PIPE: The oncolytic virus biotech sold shares to private investors including Redmile Group, RTW Investments, Boxer Capital, an unnamed life sciences-focused institutional investor and others. Earlier this month, the company announced key data for its melanoma therapy. It plans to seek FDA approval later this year. — Lei Lei Wu
Novo Nordisk taps Biosplice Therapeutics for diabetes deal: Biosplice is developing small molecule drugs that go after a key enzyme in beta cells, which are found in the pancreas and responsible for producing insulin. Novo will fund further preclinical development with an exclusive option to license certain IP from Biosplice. Financial terms of the deal were not disclosed. — Lei Lei Wu